FDA to Collaborate with ACD/Labs to Develop Predictive QSAR Models
Toronto, Canada (Nov. 4, 2010)—Advanced Chemistry Development, Inc., (ACD/Labs) announced today that the U.S. Food
and Drug Administration (FDA) and ACD/Labs will work together in a five-year research collaboration to develop quantitative
structure-activity relationship (QSAR) toxicity models for FDA regulatory and research applications. Under this collaborative
agreement, the FDA will provide non-proprietary toxicology data for the following toxicological endpoints: carcinogenicity,
genetic toxicity, reproductive toxicity, and developmental toxicity. The ACD/Labs’ Algorithm Builder program will be used to
construct and validate QSAR models, and these models will be incorporated into ACD/Tox Suite, ACD/ADME Suite, and ACD/PhysChem
Suite software. These software programs will be used to provide critical decision support information on the safety of substances
in pre- and post-market evaluations by FDA’s Center for Food Safety and Applied Nutrition (CFSAN). Under this agreement, ACD/Labs
will have the right to commercialize QSAR models that are developed from this collaboration.
"We are excited to work with the FDA on this project," said Tim Blacker, Director of Business Development and
Strategic Alliances at ACD/Labs. "This effort will leverage the combined expertise of scientists at both ACD/Labs
and the FDA to produce software that will provide value to the FDA and to the safety of the wider community in
general."
As part of this agreement, results of this collaboration will be made available to the public via publications
and presentations.
